Prime Medicine, Inc. (PRME) Covered Calls
Prime Medicine, Inc. is a clinical-stage biotechnology company developing curative genetic therapies using its proprietary Prime Editing platform. This technology acts like a DNA word processor to precisely search for and replace faulty genetic sequences at their natural location without causing double-strand DNA breaks. The company is advancing a diversified pipeline of therapies targeting serious diseases, with a core focus on indications in the liver, lung, and immunology sectors.
You can sell covered calls on Prime Medicine, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PRME (prices last updated Wed 4:16 PM ET):
| Prime Medicine, Inc. (PRME) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 3.83 | -0.22 | 3.77 | 3.89 | 2.5M | - | 0.7 |
| Covered Calls For Prime Medicine, Inc. (PRME) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 4 | 0.15 | 3.74 | 4.0% | 146% | |
| Apr 17 | 4 | 0.15 | 3.74 | 4.0% | 38.4% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Prime Medicine is pioneering the field of genetic medicine with its Prime Editing technology. Unlike traditional CRISPR systems that often rely on double-strand DNA breaks, Prime Editing is designed to make highly precise, predictable, and efficient edits to the genome without causing such breaks. This versatility allows the platform to correct a broad range of mutation types, including point mutations, insertions, and deletions, at the exact site of the pathogenic gene.
The company’s therapeutic portfolio is strategically organized around core disease areas, including liver, lung, and immunology and oncology. By developing in vivo and ex vivo therapies, Prime Medicine aims to provide long-lasting, potentially curative solutions for patients suffering from serious genetic conditions. Its research efforts are supported by advanced delivery platforms and ongoing collaborations designed to translate its precise editing tools into viable clinical-stage medicines.
Competitive Landscape
The gene editing landscape is characterized by intense research and rapid innovation. Prime Medicine competes with other biotechnology firms that are developing diverse editing platforms. Key peers in the space include:
- Beam Therapeutics (BEAM): A major competitor focused on base editing, another high-precision approach to genomic medicine.
- CRISPR Therapeutics (CRSP): A pioneer in CRISPR-Cas9 technology, competing broadly in the development of gene-edited therapies.
- Editas Medicine (EDIT): Engaged in developing CRISPR-based medicines for a variety of genetic and serious diseases.
- Intellia Therapeutics (NTLA): A leader in CRISPR-based in vivo and ex vivo therapeutic programs.
Strategic Outlook and Innovation
Prime Medicine’s strategic focus is on advancing its lead therapeutic programs through clinical development while continuing to mature its Prime Editing platform. The company aims to maximize the breadth of its technology by exploring new tissue-targeting capabilities and delivery methods.
Innovation remains tied to the ongoing optimization of its "search and replace" tools, ensuring they remain precise and efficient across an ever-widening set of genetic targets. The long-term goal is to transform the standard of care for genetic diseases by establishing Prime Editing as a robust, scalable, and curative engine for human health.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | FLY covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | S covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? PRMB Covered Calls | PRN Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
